{"id":742053,"date":"2010-09-30T15:05:00","date_gmt":"2010-09-30T15:05:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-appeal-verdict-in-massachusetts-medicaid-case\/"},"modified":"2026-08-10T13:01:14","modified_gmt":"2026-08-10T17:01:14","slug":"merck-to-appeal-verdict-in-massachusetts-medicaid-case","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-appeal-verdict-in-massachusetts-medicaid-case\/","title":{"rendered":"Merck to Appeal Verdict in Massachusetts Medicaid Case"},"content":{"rendered":"<p class=\"bwalignc\">       Says evidence showed it was not responsible for the amounts the        Commonwealth agreed to pay pharmacists     <\/p>\n<p class=\"bwalignc\">       Asserts that jury\u2019s findings are clearly against the weight of the        evidence     <\/p>\n<p>WHITEHOUSE STATION, N.J.&#8211;(BUSINESS WIRE)&#8211;Merck &amp; Co., Inc. today said it will vigorously appeal a Massachusetts        federal court jury verdict concerning allegations that a former        subsidiary of Schering-Plough Corporation, Warrick Pharmaceuticals,        caused the Commonwealth of Massachusetts to overpay local pharmacists        for prescriptions of albuterol. Merck and Schering-Plough merged in        November&nbsp;2009. Warrick ceased operations prior to the merger, in 2008.     <\/p>\n<p>       Following a 3-week trial, the jury found Merck liable for approximately        $4.6 million in compensatory damages. U.S. District Judge Patti Saris        deferred a decision on how penalties should be calculated under        Massachusetts state law. While penalties could be substantial, Merck        emphasized that significant legal issues remain to be decided by the        court before penalties could be imposed in any amount.     <\/p>\n<p>       \u201cThe company intends to vigorously pursue a reversal of the verdict in        the trial court and on appeal, if necessary,\u201d said Bruce N. Kuhlik,        executive vice president and general counsel of Merck. &#8220;We strongly        believe the evidence showed that the Commonwealth made informed choices        about amounts it paid to Massachusetts pharmacists, and that Warrick was        in no way responsible for those choices.\u201d     <\/p>\n<p>       At trial, Merck presented evidence that Warrick was never required or        asked to provide information to the Commonwealth regarding the price at        which it was selling albuterol, that the prices Warrick reported to        other parties, including other government entities, were true and        accurate, and that the Commonwealth had extensive and accurate        information regarding those prices from sources other than Warrick.     <\/p>\n<p>       \u201cWe are very disappointed with the outcome of this trial. Both the        finding of liability and the amount of compensatory damages are clearly        against the weight of the evidence,\u201d said John T. Montgomery of Ropes &amp;        Gray LLC, outside counsel for Merck. &#8220;We will promptly seek to set aside        the verdict.&#8221;     <\/p>\n<p>       The case was originally filed by the Commonwealth in 2003 and was tried        in federal court in Boston. The drugs involved in the case are three        generic albuterol products that were manufactured and sold by Warrick.     <\/p>\n<p>       <b>About Merck<\/b>     <\/p>\n<p>       Today&#8217;s Merck is a global healthcare leader working to help the world be        well. Merck is known as MSD outside the United States and Canada.        Through our prescription medicines, vaccines, biologic therapies, and        consumer care and animal health products, we work with customers and        operate in more than 140 countries to deliver innovative health        solutions. We also demonstrate our commitment to increasing access to        healthcare through far-reaching policies, programs and partnerships. For        more information, visit <a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.merck.com%2F&amp;esheet=6450615&amp;lan=en-US&amp;anchor=www.merck.com&amp;index=1&amp;md5=c29795f39f5f7847f4f92e04a0df0ce9\">www.merck.com<\/a>.     <\/p>\n<p>       <b>Forward-Looking Statement<\/b>     <\/p>\n<p>       This news release includes \u201cforward-looking statements\u201d within the        meaning of the safe harbor provisions of the United States Private        Securities Litigation Reform Act of 1995. Such statements may include,        but are not limited to, statements about the benefits of the merger        between Merck and Schering-Plough, including future financial and        operating results, the combined company\u2019s plans, objectives,        expectations and intentions and other statements that are not historical        facts. Such statements are based upon the current beliefs and        expectations of Merck\u2019s management and are subject to significant risks        and uncertainties. Actual results may differ from those set forth in the        forward-looking statements.     <\/p>\n<p>       The following factors, among others, could cause actual results to        differ from those set forth in the forward-looking statements: the        possibility that the expected synergies from the merger of Merck and        Schering-Plough will not be realized, or will not be realized within the        expected time period; the impact of pharmaceutical industry regulation        and health care legislation; the risk that the businesses will not be        integrated successfully; disruption from the merger making it more        difficult to maintain business and operational relationships; Merck\u2019s        ability to accurately predict future market conditions; dependence on        the effectiveness of Merck\u2019s patents and other protections for        innovative products; the risk of new and changing regulation and health        policies in the U.S. and internationally and the exposure to litigation        and\/or regulatory actions.     <\/p>\n<p>       Merck undertakes no obligation to publicly update any forward-looking        statement, whether as a result of new information, future events or        otherwise. Additional factors that could cause results to differ        materially from those described in the forward-looking statements can be        found in Merck\u2019s 2009 Annual Report on Form 10-K and the company\u2019s other        filings with the Securities and Exchange Commission (SEC) available at        the SEC\u2019s Internet site (<a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=6450615&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=2&amp;md5=bb1717b826e9b68b00975d00e6bdc3e6\">www.sec.gov<\/a>).     <\/p>\n<\/p>\n<p><p>       Merck &amp; Co., Inc.<br \/>Media:<br \/>Ron Rogers, 908-423-6449<br \/>or<br \/>Investors:<br \/>Joe        Romanelli, 908-423-5088     <\/p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck &amp; Co., Inc. today said it will vigorously appeal a Massachusetts federal court jury verdict concerning allegations that a former subsidiary of Schering-Plough Corporation, Warrick Pharmaceuticals, caused the Commonwealth of Massachusetts to overpay local pharmacists for prescriptions of albuterol. Merck and Schering-Plough merged in November&nbsp;2009. Warrick ceased operations prior to the merger, in 2008. Following a 3-week trial, the jury found Merck liable for approximately $4.6 million in compensatory damages. U.S. District Judge Patti Saris deferred a decision on how penalties should be calculated under Massachusetts state law. While penalties could be substantial, Merck emphasized that significant legal issues remain to be decided by the court before penalties could be imposed in any amount. \u201cThe company intends to vigorously pursue a reversal of the verdict in the trial court and on appeal, if necessary,\u201d said Bruce N. Kuhlik, executive vice president and general<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,289],"class_list":["post-742053","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck to Appeal Verdict in Massachusetts Medicaid Case - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-appeal-verdict-in-massachusetts-medicaid-case\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck to Appeal Verdict in Massachusetts Medicaid Case - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck &amp; Co., Inc. today said it will vigorously appeal a Massachusetts federal court jury verdict concerning allegations that a former subsidiary of Schering-Plough Corporation, Warrick Pharmaceuticals, caused the Commonwealth of Massachusetts to overpay local pharmacists for prescriptions of albuterol. Merck and Schering-Plough merged in November&nbsp;2009. Warrick ceased operations prior to the merger, in 2008. Following a 3-week trial, the jury found Merck liable for approximately $4.6 million in compensatory damages. U.S. District Judge Patti Saris deferred a decision on how penalties should be calculated under Massachusetts state law. While penalties could be substantial, Merck emphasized that significant legal issues remain to be decided by the court before penalties could be imposed in any amount. \u201cThe company intends to vigorously pursue a reversal of the verdict in the trial court and on appeal, if necessary,\u201d said Bruce N. Kuhlik, executive vice president and general\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-appeal-verdict-in-massachusetts-medicaid-case\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-10T17:01:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-appeal-verdict-in-massachusetts-medicaid-case\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-appeal-verdict-in-massachusetts-medicaid-case\\\/\",\"name\":\"Merck to Appeal Verdict in Massachusetts Medicaid Case - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2010-09-30T15:05:00+00:00\",\"dateModified\":\"2026-08-10T17:01:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-appeal-verdict-in-massachusetts-medicaid-case\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-appeal-verdict-in-massachusetts-medicaid-case\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-appeal-verdict-in-massachusetts-medicaid-case\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck to Appeal Verdict in Massachusetts Medicaid Case\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck to Appeal Verdict in Massachusetts Medicaid Case - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-appeal-verdict-in-massachusetts-medicaid-case\/","og_locale":"en_US","og_type":"article","og_title":"Merck to Appeal Verdict in Massachusetts Medicaid Case - Merck.com","og_description":"Merck &amp; Co., Inc. today said it will vigorously appeal a Massachusetts federal court jury verdict concerning allegations that a former subsidiary of Schering-Plough Corporation, Warrick Pharmaceuticals, caused the Commonwealth of Massachusetts to overpay local pharmacists for prescriptions of albuterol. Merck and Schering-Plough merged in November&nbsp;2009. Warrick ceased operations prior to the merger, in 2008. Following a 3-week trial, the jury found Merck liable for approximately $4.6 million in compensatory damages. U.S. District Judge Patti Saris deferred a decision on how penalties should be calculated under Massachusetts state law. While penalties could be substantial, Merck emphasized that significant legal issues remain to be decided by the court before penalties could be imposed in any amount. \u201cThe company intends to vigorously pursue a reversal of the verdict in the trial court and on appeal, if necessary,\u201d said Bruce N. Kuhlik, executive vice president and general","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-appeal-verdict-in-massachusetts-medicaid-case\/","og_site_name":"Merck.com","article_modified_time":"2026-08-10T17:01:14+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-appeal-verdict-in-massachusetts-medicaid-case\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-appeal-verdict-in-massachusetts-medicaid-case\/","name":"Merck to Appeal Verdict in Massachusetts Medicaid Case - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2010-09-30T15:05:00+00:00","dateModified":"2026-08-10T17:01:14+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-appeal-verdict-in-massachusetts-medicaid-case\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-appeal-verdict-in-massachusetts-medicaid-case\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-appeal-verdict-in-massachusetts-medicaid-case\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck to Appeal Verdict in Massachusetts Medicaid Case"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"3455548d-1dd3-4f8b-9223-d7f80f30734b","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-to-Appeal-Verdict-in-Massachusetts-Medicaid-Case-2010.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742053","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742053\/revisions"}],"predecessor-version":[{"id":3679191,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742053\/revisions\/3679191"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742053"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742053"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}